Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 121-129

  McEwan, Phil ^a,b   Peters, John R ^c   Bergenheim, Klas ^d   Currie, Craig J ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Cardiff Research Consortium   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

Cost effectiveness; Cost utility; Economics; QALY; Risk factors; Type 2 diabetes

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIFF STOCHASTIC SIMULATION COST UTILITY MODEL; CHOLESTEROL BLOOD LEVEL; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; RELIABILITY; RISK FACTOR; RISK REDUCTION; SIMULATION; STOCHASTIC MODEL; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROGNOSIS; RISK FACTORS; STOCHASTIC PROCESSES; TREATMENT OUTCOME;

EID: 30844465261     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80350     Document Type: Article

References (28)

1. Bagust A, Hopkinson PK, Maier W, et al. An economic model of the long-term health care burden of Type II diabetes. Diabetologia 2001;44:2140-55
2. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26
3. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 1997;20:725-34
4. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
5. Brown JB, Palmer AJ, Bisgaard P, et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Pract 2000;50(Suppl 3):S57-S64
6. Currie CJ, Morgan CLI, Dixon S, et al. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death. Diabetes Res Clin Pract 2005;67:144-51
7. Currie CJ, Morgan CLI, Dixon S, et al. The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications. Diabetes Res Clin Pract 2005;67:144-51
8. Evans M, McEwan P, Peters JR, et al. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate. Diabetes Obes Metab 2004;6:299-307
9. Soedamah-Muthu SS, Chaturvedi N, Toeller M, et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004;27:530-37
10. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991;12:293-8
11. Stevens RJ, Kothari V, Adler AI, Stratton IM. United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2000;101:671-9
12. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81
13. Currie CJ, McEwan P, Peters JR, et al. The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 Subjects. Value Health 2005;8:581-90
14. Clarke P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabetic Med 2003;20:442-50
15. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998;21:42-8
16. British National Formulary [online]. Available from www.bnf. org/ [Last Accessed 2 Feb 2004)
17. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 2000;321:405-12
18. Morgan CL, Curie CJ, Peters J. Relationship between diabetes and mortality. Diabetes Care 2000;23:1103-7
19. Currie CJ, Morgan CL, Gill L, et al. Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations. Stroke 1997;28:1142-6
20. Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997;78:544-9
21. Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20(Suppl 1):S53-S58
22. The CDC Diabetes Cost-Effectiveness Group. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. JAMA 2002;287:2542-51
23. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
24. Clarke P, Grau A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340-9
25. Lee AJ, Morgan CLI, Morrissey M, et al. Evaluation of the association between the EQ-5D index (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005;22:1482-6
26. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-83
27. Currie CJ, McEwan M, Poole CD, et al. The impact of the overactive bladder on health-related utility and quality of life. BJU International (in press)
28. Lee AJ, Morgan CLI, Conway P, et al. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin 2005;21:1777-83